U.S.-Russian duo returns to Earth from space station
MOSCOW (Reuters) - A Russian Soyuz space capsule carrying a U.S. astronaut and a Russian cosmonaut from the International Space Station landed safely in Kazakhstan on Thursday.
MOSCOW (Reuters) - A Russian Soyuz space capsule carrying a U.S. astronaut and a Russian cosmonaut from the International Space Station landed safely in Kazakhstan on Thursday.
LONDON (Reuters) - German scientists have created a three-dimensional “invisibility cloak” that can hide objects by bending light waves.
NEW YORK (Reuters) - The Dow industrials rose on Thursday on Boeing’s strength, while the S&P 500 slipped after a round of economic data and corporate results.
LOS ANGELES (Reuters) - From French poodles to German shepherds, domestic dogs likely trace most of their ancestry to the Middle East, as opposed to East Asian origins suggested by previous research, a genetic study reported on Wednesday.
WASHINGTON (Reuters) - Four top Federal Reserve officials chiefs urged Congress on Thursday not to strip the U.S. central bank of the authority to supervise small banks, saying they would lose an important finger on the pulse of the economy that helps them guide monetary policy.
WASHINGTON (Reuters) - The economy is on a moderate growth path and inflation pressures are contained, data showed Thursday, backing up the Federal Reserve’s vow to keep benchmark interest rates ultra-low for some time.
WASHINGTON (Reuters) - The tension level in the debate on financial reform rose on Thursday as Democrats slapped back at a Republican leader’s comment about “punk staffers” and a pivotal vote neared in the Senate.
LONDON (Reuters) - It’s been a bad month for Pfizer’s research labs but its head of R&D says the world’s biggest drugmaker is on track to hit earlier targets for new drug filings despite the setbacks.
NEW YORK (Reuters) - FedEx Corp raised its fiscal-year outlook on Thursday after quarterly profit more than doubled, with strong Asian export volumes more than compensating for flat U.S. demand.
FRANKFURT (Reuters) - Israel’s Teva has won the battle for German generic drugmaker Ratiopharm, paying an enterprise value of 3.625 billion euros to fix the industry leader’s weakness in the world’s second-largest generics market.
| | | |
Powered by WordPress